Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | CD5.CAR T-cell therapy in patients with T-cell lymphoma

LaQuisa Hill, MD, Texas Children’s Hospital, Houston Methodist Hospital, Houston, TX, presents updates from a Phase I trial (NCT03081910) assessing autologous CD5-specific chimeric antigen receptor (CD5.CAR) T-cell therapy in patients with T-cell lymphoma. In a cohort of nine patients who were treated, an increased dose level was administered and encouraging responses were reported, with three patients being able to proceed to transplant. Dr Hill additionally highlights changes in the manufacturing process since data were first reported. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.